Systems Toxicology to Assess Reduced Risk Tobacco Products
Philip Morris International (PMI) is developing a portfolio of potentially reduced-risk tobacco products. We are currently assessing their risk reduction potential and would like to invite you to attend a scientific symposium to preview and discuss our current research in this area on September 8th, 2014 in Edinburgh, UK. This PMI-hosted scientific symposium will be an opportunity to hear about the Systems Toxicology research PMI is conducting to assess these new products and to get your input on our approaches.
Schedule
8 September
C Mathis
Systems Toxicology-Based Assessment of a RRP using Human Organotypic Tissue Cultures of Nasal and Bronchial Epithelium as well as Buccal Mucosa
8 September
Aqueous cigarette smoke extract promotes the adhesion of monocytic cells to human coronary arterial endothelial cells in direct and indirect-dependent ways
8 September
C Mathis
Reduced Impact of a Prototypic Modified Risk Tobacco Product Compared with Conventional Cigarette Smoke on Exposed Human and Rat Primary Normal Bronchial Epithelial Cells
8 September
E Bilal
Verification Of Systems Biology Research In The Age Of Collaborative Competition
8 September
I Gonzalez-Suarez
Multiplexed High Content Screening Analysis Reveals Reduced Toxicity Of A Prototypic Modified Risk Tobacco Product (pMRTP) As Compared To A Conventional Cigarette
8 September
A Mechanistic Study Of Cigarette Smoke-Induced COPD In C57BL/6 Mice: The Impact Of Switching To pMRTP